Faecal immunochemical tests (FITs) for haemoglobin are now widely used in asymptomatic screening for bowel cancer and in assessment of patients presenting with lower bowel symptoms. The FIT might also be of value in other clinical settings such as surveillance of patients with previous bowel disease. Quantitative FIT provides estimates of faecal haemoglobin (f-Hb) concentration for use in all of these cases.
It is now well documented that the f-Hb is related to the severity of bowel disease. Thus, lowering the f-Hb cut-off used to trigger clinical action confers better detection of bowel cancer, adenoma and other serious bowel pathology. The clinical sensitivity increases, but the positivity rises, the demand for colonoscopy increases, the number of false-positive results rises, and the positive predictive value falls.
As a number of users of FIT in assessment of symptomatic patients see cancer detection as the most important role, there is considerab